Health Condition 1: L501- Idiopathic urticaria
Conditions
Interventions
Intervention1: Bilastine: Bilastine 20 mg once daily for 6 weeks
Intervention2: Bilastine: Bilastine 20 mg once daily for 6 weeks.
Control Intervention1: Levocetirizine: Levocetirizine 5 mg once daily
Sponsors
AIIMS Jodhpur
Eligibility
Inclusion criteria
Inclusion criteria: Wilfully consenting patients with chronic spontaneous urticaria, aged 18-65 years will be included in the study.
Exclusion criteria
Exclusion criteria: Drivers and people working with heavy machinery. Ongoing treatment with Omalizumab, or Cyclosporin A. Systemic illness like chronic liver disease or chronic kidney disease. Pregnancy and lactation. Known hypersensitivity to any of the drugs included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the clinical improvement between Levocetirizine, Bilastine, and Fexofenadine treatment groups in the treatment of Chronic Spontaneous Urticaria using UAS7.Timepoint: At baseline and then every 2 weeks for 6 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the pre and post-treatment basophil count between the three treatment groups. To assess the effect of treatment on CU-Q2oL and DLQI. To compare the side-effects between different treatment groups. Timepoint: At baseline and then every 2 weeks for 6 weeks. | — |
Countries
India
Contacts
Public ContactDr Shilpi Tyagi
AIIMS
Outcome results
None listed